Marine cyanobacteria compounds with anticancer properties: Implication of apoptosis

Handbook of Anticancer Drugs from Marine Origin

Volumn , Issue , 2015, Pages 621-647

  Martins, Maria Do Ros�rio ^a   Costa, Margarida ^b  

^a POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Anticancer compounds; Apoptose; Marine cyanobacteria

Indexed keywords

EID: 84944611482     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-07145-9_29     Document Type: Chapter

References (130)

1. Amon A (1999) The spindle checkpoint. Curr Opin Genet Dev 9 (1):69-75
2. Andrianasolo EH et al (2005) Isolation of swinholide A and related glycosylated derivative from two field collections of marine cyanobacteria. Org Lett 7 (7):1375-1378
3. Balunas MJ et al (2012) Coibacins A-D, antileishmanial marine cyanobacterial polyketides with intriguing biosynthetic origins. Org Lett 14 (15):3878-3881
4. Barnhart BC et al (2004) CD95 ligand induces motility and invasiveness of apoptosis-resis- tant tumor cells. Embo J 23 (15):3175-3185
5. Barrett AJ (1981) Leukocyte elastase. Methods Enzymol 80:581-588
6. Beckwith M, Urba WJ, Longo DL (1993) Longo, growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Natl Cancer Inst 85 (6):483-488
7. Bernardo PH et al (2007) Structure-activity delineation of quinones related to the biologically active Calothrixin B. Bioorg Med Chem Lett 17 (1):82-85
8. Boudreau PD et al (2012) Viequeamide A, a cytotoxic member of the kulolide superfamily of cyclic depsipeptides from a marine button cyanobacterium. J Nat Prod 75(9):1560-1570
9. Carpenter EJ, Subramaniam A, Capone DG (2004) Biomass and primary productivity of the cyanobacterium Trichodesmium spp. In the tropical N Atlantic ocean. Deep-Sea Res Part I- Oceanogr Res Pap 51 (2):73-203
10. Castenholz RW (2001) General characteristics of the cyanobacteria. In: D.R.B.R.W.C. (Ed) Bergey’s manual of systematic bacteriology. Springer, New York, pp 474-487
11. Catassi A et al (2006) Characterization of apoptosis induced by marine natural products in non small cell lung cancer A549 cells. Cell Mol Life Sci 63 (19-20):2377-2386
12. Chang TT et al (2011) Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro. Eur J Med Chem 46 (9):3810-3819
13. Chen XX, Smith GD, Waring P (2003) Human cancer cell (Jurkat) killing by the cyanobacterial metabolite calothrixin A. J Appl Phycol 15 (4):269-277
14. Choi H et al (2010) The hoiamides, structurally intriguing neurotoxic lipopeptides from Papua New Guinea marine cyanobacteria. J Nat Prod 73 (8):1411-1421
15. Choi H et al (2012) Lyngbyabellins K-N from two Palmyra Atoll collections of the marine CyanobacteriumMoorea bouillonii. Eur J Org Chem 27:5141-5150
16. Costa M et al (2012) Marine cyanobacteria compounds with anticancer properties: a review on the implication of apoptosis. Mar Drugs 10 (10):2181-2207
17. Costa M et al (2014) Exploring bioactive properties of marine cyanobacteria isolated from the Portuguese coast: high potential as a source of anticancer compounds. Mar Drugs 12(1):98-114
18. Costa-Rodrigues J et al (2012) Cytotoxicity of marine cyanobacteria extracts on osteosarcoma cells. Bone 50:S181-S182
19. Davies-Coleman MT et al (2003) Isolation of homodolastatin 16, a new cyclic depsipeptide from a Kenyan collection ofLyngbya majuscula. J Nat Prod 66 (5):712-715
20. Droga-Mazovec G, Bojic L, Petelin A, Ivanova S, Romih R, Repnik U, Salvesen GS, Stoka V Turk V, Turk B (2008) Cysteine Cathepsins Trigger Caspase-dependent Cell Death through Cleavage of Bid and Antiapoptotic Bcl-2 Homologues. J Biol Chem 283 (27):19140-19150
21. Edwards DJ et al (2004) Structure and biosynthesis of the jamaicamides, new mixed polyketide-peptide neurotoxins from the marine cyanobacterium Lyngbya majuscula. Chem Biol 11 (6):817-833
22. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35 (4):495-516
23. Engene N et al (2011) Underestimated biodiversity as a major explanation for the perceived rich secondary metabolite capacity of the cyanobacterial genus Lyngbya. Environ Microbiol 13 (6):1601-1610
24. Engene N et al (2012) Moorea producens gen. Nov., sp. Nov. And Moorea bouillonii comb. Nov., tropical marine cyanobacteria rich in bioactive secondary metabolites. Int J Syst Evol Microbiol 62(Pt 5):1171-1178
25. Folmer F et al (2010) Photosynthetic marine organisms as a source of anticancer compounds. Phytochem Rev 9 (4):557-579
26. Gerwick WH et al (1994) Structure of Curacin A, a novel antimitotic, antiproliferative, and brine shrimp toxic natural product from the marine cyanobacterium Lyngbya majuscula. J Org Chem 59:1243-1245
27. Gerwick WH et al (2008) Giant marine cyanobacteria produce exciting potential pharmaceuticals. Microbe 3:8
28. Golakoti T et al (2001) Isolation and structure determination of nostocyclopeptides A1 and A2 from the terrestrial cyanobacterium Nostoc sp. Atcc53789. J Nat Prod 64 (1):54-59
29. Gregory CD, Devitt A (2004) The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? Immunology 113 (1):1-14
30. Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13 (15):1899-1911
31. Gross H et al (2010) Two cytotoxic stereoisomers of malyngamide C, 8-epi-malyngamide C and 8-O-acetyl-8-epi-malyngamide C, from the marine cyanobacterium Lyngbya majuscula. Phytochemistry 71 (14-15):1729-1735
32. Gunasekera SP et al (2008) Dragonamides C and D, linear lipopeptides from the marine cyanobacterium brown Lyngbyapolychroa. J Nat Prod 71 (5):887-890
33. Gunasekera SP et al (2010) Molassamide, a depsipeptide serine protease inhibitor from the marine cyanobacterium Dichothrix utahensis. J Nat Prod 73 (3):459-462
34. Gutierrez M et al (2008) Apratoxin D, a potent cytotoxic cyclodepsipeptide from papua new guinea collections of the marine cyanobacteria Lyngbya majuscula and Lyngbya sordida. J Nat Prod 71 (6):1099-1103
35. Gutierrez M et al (2010) Malyngolide dimer, a bioactive symmetric cyclodepside from the panamanian marine cyanobacterium Lyngbya majuscula. J Nat Prod 73 (4):709-711
36. Han B et al (2005) The wewakpeptins, cyclic depsipeptides from a Papua new guinea collection of the marine cyanobacterium Lyngbya semiplena. J Org Chem 70 (8):3133-3139
37. Han BN et al (2005) Isolation and structure of five lyngbyabellin derivatives from a Papua new guinea collection of the marine cyanobacterium Lyngbya majuscula. Tetrahedron 61 (49):11723-11729
38. Han B et al (2006) Aurilides B and C, cancer cell toxins from a Papua new guinea collection of the marine cyanobacterium Lyngbya majuscula. J Nat Prod 69 (4):572-575
39. Harrigan GG et al (1998) Symplostatin 1: a dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. J Nat Prod 61 (9):1075-1077
40. Hartman H (1998) Photosynthesis and the origin of life. Orig Life Evol Biosph 28:515-521
41. Hau AM et al (2013) Coibamide A induces mTOR-independent autophagy and cell death in human glioblastoma cells. Plos One 8 (6):e65250
42. Horgen FD et al (2002) Malevamide D: isolation and structure determination of an isodol- astatin H analogue from the marine cyanobacterium Symploca hydnoides. J Nat Prod 65 (4):487-491
43. Jimenez JI, Scheuer PJ (2001) New lipopeptides from the Caribbean cyanobacterium Lyng- bya majuscula. J Nat Prod 64 (2):200-203
44. Jones AC et al (2010) The unique mechanistic transformations involved in the biosynthesis of modular natural products from marine cyanobacteria. Nat Prod Rep 27 (7):1048-1065
45. Jordan MA, Wilson L (1998) Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10 (1):123-130
46. Kalemkerian GP et al (1999) Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 43 (6):507-515
47. Keepers YP et al (1991) Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27 (7):897-900
48. Khan QA, Lu J, Hecht SM (2009) Calothrixins, a new class of human DNA topoisomerase I poisons. J Nat Prod 72 (3):438-442
49. Kobayashi H, Shinohara H, Takeuchi K, Itoh M, Fujie M, Saitoh M and Terao T (1994) Inhibition of the soluble and tumor cell receptorbound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. Cancer Res 54 (3): 844-849
50. Kurokawa M, Kornbluth S (2009) Caspases and kinases in a death grip. Cell 138 (5):838-854
51. Kwan JC et al (2009) Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem 52 (18):5732-5747
52. Kwan JC et al (2009) Lyngbyastatins 8-10, elastase inhibitors with cyclic depsipeptide scaffolds isolated from the marine cyanobacterium Lyngbya semiplena. Mar Drugs 7 (4):528-538
53. Leao PN et al (2013) Antitumor activity of Hierridin B, a cyanobacterial secondary metabolite found in both filamentous and unicellular marine strains. Plos One 8 (7):e69562
54. Linington RG et al (2008) Symplocamide A, a potent cytotoxin and chymotrypsin inhibitor from the marine Cyanobacterium Symploca sp. J Nat Prod 71 (1):22-27
55. Luesch H et al (2000) Isolation, structure determination, and biological activity of Lyngbya- bellin A from the marine cyanobacterium Lyngbya majuscula. J Nat Prod 63 (5):611-615
56. Luesch H et al (2001) Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplo- statin 1. J Nat Prod 64 (7):907-910
57. Luesch H et al (2001) Pitipeptolides A and B, new cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula. J Nat Prod 64 (3):304-307
58. Luesch H et al (2001) Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula. J Am Chem Soc 123 (23):5418-5423
59. Luesch H et al (2002) Lyngbyaloside B, a new glycoside macrolide from a Palauan marine cyanobacterium, Lyngbya sp. J Nat Prod 65 (12):1945-1948
60. Luesch H et al (2002) New apratoxins of marine cyanobacterial origin from Guam and Palau. Bioorg Med Chem 10 (6):1973-1978
61. Luesch H et al (2002) Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. Vp452. J Nat Prod 65 (1):16-20
62. Ma D et al (2006) Total synthesis of the cyclodepsipeptide apratoxin A and its analogues and assessment of their biological activities. Chemistry 12 (29):7615-7626
63. MacMillan JB, Molinski TF (2002) Caylobolide A, a unique 36-membered macrolactone from a Bahamian Lyngbya majuscula. Org Lett 4 (9):1535-1538
64. Malloy KL et al (2011) Malyngamide 2, an oxidized lipopeptide with nitric oxide inhibiting activity from a Papua new guinea marine cyanobacterium. J Nat Prod 74 (1):95-98
65. Marquez BL et al (2002) Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly. J Nat Prod 65 (6):866-871
66. Martins RF et al (2008) Antimicrobial and cytotoxic assessment of marine cyanobacteria- Synechocystis and Synechococcus. Mar Drugs 6 (1):1-11
67. Martins R et al (2013) Cytotoxicity of picocyanobacteria strains of the genera Cyanobium on osteosarcoma cells. In: European calcified tissue society conference ECTS 2013. Lisbon (Portugal)
68. Matthew S et al (2007) Lyngbyastatin 4, a dolastatin 13 analogue with elastase and chymotrypsin inhibitory activity from the marine cyanobacterium Lyngbya confervoides. J Nat Prod 70 (1):124-127
69. Matthew S, Schupp PJ, Luesch H (2008) Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium Lyngbya bouillonii. J Nat Prod 71 (6):1113-1116
70. Matthew S et al (2008) Pompanopeptins A and B, new cyclic peptides from the marine cyanobacterium Lyngbya confervoides. Tetrahedron 64 (18):4081-4089
71. Matthew S, Paul VJ, Luesch H (2009) Largamides A-C, tiglic acid-containing cyclodepsi- peptides with elastase-inhibitory activity from the marine cyanobacterium Lyngbya confer- voides.Planta Med 75 (5):528-533
72. Matthew S, Paul VJ, Luesch H (2009) Tiglicamides A-C, cyclodepsipeptides from the marine cyanobacterium Lyngbya confervoides. Phytochemistry 70 (17-18):2058-2063
73. Matthew S et al (2010) Cytotoxic halogenated macrolides and modified peptides from the apratoxin-producing marine cyanobacterium Lyngbya bouillonii from Guam. J Nat Prod 73 (9):1544-1552
74. Medina RA et al (2008) Coibamide A, a potent antiproliferative cyclic depsipeptide from the Panamanian marine cyanobacterium Leptolyngbya sp. J Am Chem Soc 130 (20):6324-6325
75. Mevers E et al (2011) Cytotoxic veraguamides, alkynyl bromide-containing cyclic dep- sipeptides from the marine cyanobacterium cf. Oscillatoria margaritifera. J Nat Prod 74 (5):928-936
76. Molinski TF et al (2009) Drug development from marine natural products. Nat Rev Drug Discov 8 (1):69-85
77. Montaser R, Paul VJ, Luesch H (2011) Pitipeptolides C-F, antimycobacterial cyclodepsip- eptides from the marine cyanobacterium Lyngbya majuscula from Guam. Phytochemistry 72 (16):2068-2074
78. Montaser R et al (2011) Pitiprolamide, a proline-rich dolastatin 16 analogue from the marine cyanobacterium Lyngbya majuscula from Guam. J Nat Prod 74 (1):109-112
79. Mooberry SL, Busquets L, Tien G (1997) Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent. Int J Cancer 73 (3):440-448
80. Mooberry SL et al (2003) The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog. Int J Cancer 104 (4):512-521
81. Moroy G, Alix AJP, Sapi J, Hornebeck W, Bourguet E (2012) Neutrophil Elastase as a Target in Lung Cancer. Anti-Cancer Agents Med Chem 12 (6):565-579
82. Nogle LM, Okino T, Gerwick WH (2001) Antillatoxin B, a neurotoxic lipopeptide from the marine cyanobacterium Lyngbya majuscula. J Nat Prod 64 (7):983-985
83. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (4):609-619
84. Paerl HW (2002) Marine plankton. In: Whitton BA, Potts M (eds) The ecology of cyanobacteria. Springer, Netherlands, pp 121-148
85. Pereira AR et al (2012) The Carmaphycins: new proteasome inhibitors exhibiting an alpha, beta-epoxyketone warhead from a marine cyanobacterium. Chembiochem 13 (6):810-817
86. Pettit GR et al (2008) Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms (1a). J Nat Prod 71 (3):438-444
87. Pitot HC et al (1999) Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5 (3):525-531
88. Plaza A, Bewley CA (2006) Largamides A-H, unusual cyclic peptides from the marine cyanobacterium Oscillatoria sp. J Org Chem 71 (18):6898-6907
89. Pop C, Salvesen GS (2009) Human caspases: activation, specificity, and regulation. J Biol Chem 284 (33):21777-21781
90. Rubio BK et al (2010) Depsipeptides from a Guamanian marine cyanobacterium, Lyngbya bouillonii, with selective inhibition of serine proteases. Tetrahedron Lett 51 (51):6718-6721
91. Salvador LA, Paul VJ, Luesch H (2010) Caylobolide B, a macrolactone from symplo- statin 1-producing marine cyanobacteria Phormidium spp. From Florida. J Nat Prod 73 (9):1606-1609
92. Salvador LA et al (2011) Veraguamides A-G, cyclic hexadepsipeptides from a dolastatin 16-producing cyanobacterium Symploca cf. Hydnoides from Guam. J Nat Prod 74(5):917- 927
93. Schopf WJ (2000) The fossil record: tracing the roots of the cyanobacterial lineage. In: Whitton BA, Potts M (eds) The ecology of cyanobacteria. Their diversity in time and space. Dordrecht, Kluwer Academic Publishers
94. Selheim F et al (2005) Neuro-apoptogenic and blood platelet targeting toxins in benthic marine cyanobacteria from the Portuguese coast. Aquat Toxicol 74 (4):294-306
95. Shaala LA et al (2013) Malyngamide 4, a new lipopeptide from the Red sea marine cyanobacterium Moorea producens (formerly Lyngbya majuscula). Phytochem Lett 6(2):183- 188
96. Shi YG (2004) Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci 13 (8):1979-1987
97. Simmons TL et al (2006) Belamide A, a new antimitotic tetrapeptide from a Panamanian marine cyanobacterium. Tetrahedron Lett 47 (20):3387-3390
98. Singh RK et al (2011) Cyanobacteria: an emerging source for drug discovery. J Antibiot (Tokyo) 64(6):401-412
99. Sisay MT et al (2009) Inhibition of human leukocyte elastase by brunsvicamides a-C: cyanobacterial cyclic peptides. Chemmedchem 4 (9):1425-1429
100. Slee EA, Adrain C, Martin SJ (2001) Executioner caspase-3, -6, and -7 perform distinct, nonredundant roles during the demolition phase of apoptosis. J Biol Chem 276 (10):7320-7326
101. Soreide K, Janssen EA, Korner H, Baak JP (2006) Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J Pathol 209 (2): 147-156
102. Song JS, Kang CH, Rhee CK, Yoon HK, Kim YK, Moon HS, Park SH (2009) Effects od elastase inhibitor on the epithelial cell apoptosis in bleomycin pulmonary fibrosis. Exp Lung Res 35 (10): 817-829
103. Soria-Mercado IE et al (2009) Alotamide A, a novel neuropharmacological agent from the marine cyanobacterium Lyngbya bouillonii. Org Lett 11 (20):4704-4707
104. Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, Ellerby LM, Bredesen D, Freeze H, Abrahamson M, Bromme D, Krajewski S, Reed JC, Yin XM, Turk V, Salvesen GS (2001) Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem 276(5): 3149-3157
105. Taniguchi M et al (2010) Palmyramide A, a cyclic depsipeptide from a Palmyra Atoll collection of the marine cyanobacterium Lyngbya majuscula. J Nat Prod 73 (3):393-398
106. Taori K et al (2007) Lyngbyastatins 5-7, potent elastase inhibitors from Floridian marine cyanobacteria, Lyngbya spp. J Nat Prod 70 (10):1593-1600
107. Taori K, Paul VJ, Luesch H (2008) Kempopeptins A and B, serine protease inhibitors with different selectivity profiles from a marine cyanobacterium, Lyngbya sp. J Nat Prod 71 (9):1625-1629
108. Taori K, Paul VJ, Luesch H (2008) Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc 130 (6):1806-1807
109. Teruya T et al (2009) Bisebromoamide, a potent cytotoxic peptide from the marine cyanobacterium Lyngbya sp.: isolation, stereostructure, and biological activity. Org Lett 11 (21):5062-5065
110. Teruya T et al (2009) Biselyngbyaside, a macrolide glycoside from the marine cyanobacterium Lyngbya sp. Org Lett 11 (11):2421-2424
111. Thornburg CC et al (2013) Apratoxin H and apratoxin A sulfoxide from the Red sea cyanobacterium Moorea producens. J Nat Prod 76 (9):1781-1788
112. Tidgewell K et al (2010) Evolved diversification of a modular natural product pathway: apratoxins F and G, two cytotoxic cyclic depsipeptides from a Palmyra collection of Lyngbya bouillonii. Chembiochem 11 (10):1458-1466
113. Tripathi A et al (2011) Lagunamide C, a cytotoxic cyclodepsipeptide from the marine cyanobacterium Lyngbya majuscula. Phytochemistry 72:2369-2375
114. Tripathi A et al (2012) Biochemical studies of the lagunamides, potent cytotoxic cyclic depsipeptides from the marine cyanobacterium Lyngbya majuscula. Mar Drugs 10(5):1126—1137
115. Turk B (2006) Targeting proteases: successes, failures and future prospects. Nature Rev 5 (9):785-799
116. Turner T et al (1998) Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Prostate 34 (3):175-181
117. Wall NR, Mohammad RM, Al-Katib AM (1999) Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh. Leuk Res 23 (10):881-888
118. White JD et al (2004) Total synthesis and biological evaluation of + -kalkitoxin, a cytotoxic metabolite of the cyanobacterium Lyngbya majuscula. Org Biomol Chem 2 (14):2092-2102
119. Wiegand C, Pflugmacher S (2005) Ecotoxicological effects of selected cyanobacterial secondary metabolites a short review. Toxicol Appl Pharmacol 203 (3):201-218
120. Williams PG et al (2002) Isolation and structure determination of obyanamide, a novel cytotoxic cyclic depsipeptide from the marine cyanobacterium Lyngbya confervoides. J Nat Prod 65 (1):29-31
121. Williams PG et al (2002) Tasiamide, a cytotoxic peptide from the marine cyanobacterium Symploca sp. J Nat Prod 65 (9):1336-1339
122. Williams PG et al (2003) Tasipeptins A and B: new cytotoxic depsipeptides from the marine cyanobacterium Symploca sp. J Nat Prod 66 (5):620-624
123. Williams PG et al (2003) The isolation and structure elucidation of Tasiamide B, a 4-amino- 3-hydroxy-5-phenylpentanoic acid containing peptide from the marine Cyanobacterium Symploca sp. J Nat Prod 66 (7):1006-1009
124. Williams PG et al (2003) The structure of Palau’amide, a potent cytotoxin from a species of the marine cyanobacterium Lyngbya. J Nat Prod 66 (12):1545-1549
125. Williams PG et al (2003) Ulongapeptin, a cytotoxic cyclic depsipeptide from a Palauan marine cyanobacterium Lyngbya sp. J Nat Prod 66 (5):651-654
126. Wong RS (2011) Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30:87
127. Wrasidlo W et al (2008) The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. Proc Natl Acad Sci U S A 105 (7):2313-2318
128. Yonezawa T et al (2012) Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts. J Cell Biochem 113 (2):440-448
129. Zeng X et al (2010) Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells. Org Lett 12 (6):1368-1371
130. Zou B, Long K, Ma DW (2005) Total synthesis and cytotoxicity studies of a cyclic depsipeptide with proposed structure of palau’amide. Org Lett 7 (19):4237-4240